197 related articles for article (PubMed ID: 36853944)
21. NF-κB2 mutation targets survival, proliferation and differentiation pathways in the pathogenesis of plasma cell tumors.
McCarthy BA; Yang L; Ding J; Ren M; King W; ElSalanty M; Zakhary I; Sharawy M; Cui H; Ding HF
BMC Cancer; 2012 May; 12():203. PubMed ID: 22642622
[TBL] [Abstract][Full Text] [Related]
22. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
[TBL] [Abstract][Full Text] [Related]
23. Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation.
Diamantidis MD; Papadaki S; Hatjiharissi E
Front Oncol; 2022; 12():934008. PubMed ID: 35982976
[TBL] [Abstract][Full Text] [Related]
24. Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma.
Alvarez-Benayas J; Trasanidis N; Katsarou A; Ponnusamy K; Chaidos A; May PC; Xiao X; Bua M; Atta M; Roberts IAG; Auner HW; Hatjiharissi E; Papaioannou M; Caputo VS; Sudbery IM; Karadimitris A
Nat Commun; 2021 Sep; 12(1):5450. PubMed ID: 34521827
[TBL] [Abstract][Full Text] [Related]
25. MMSET I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells.
Xie Z; Chooi JY; Toh SHM; Yang D; Basri NB; Ho YS; Chng WJ
Leukemia; 2019 Mar; 33(3):739-748. PubMed ID: 30470837
[TBL] [Abstract][Full Text] [Related]
26. Constitutive activation of IKK2/NF-κB impairs osteogenesis and skeletal development.
Swarnkar G; Zhang K; Mbalaviele G; Long F; Abu-Amer Y
PLoS One; 2014; 9(3):e91421. PubMed ID: 24618907
[TBL] [Abstract][Full Text] [Related]
27. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells.
Walker BA; Wardell CP; Johnson DC; Kaiser MF; Begum DB; Dahir NB; Ross FM; Davies FE; Gonzalez D; Morgan GJ
Blood; 2013 Apr; 121(17):3413-9. PubMed ID: 23435460
[TBL] [Abstract][Full Text] [Related]
28. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Moreaux J; Klein B; Bataille R; Descamps G; Maïga S; Hose D; Goldschmidt H; Jauch A; Rème T; Jourdan M; Amiot M; Pellat-Deceunynck C
Haematologica; 2011 Apr; 96(4):574-82. PubMed ID: 21173094
[TBL] [Abstract][Full Text] [Related]
29. Moderate activation of IKK2-NF-kB in unstressed adult mouse liver induces cytoprotective genes and lipogenesis without apparent signs of inflammation or fibrosis.
Lu H; Lei X; Zhang Q
BMC Gastroenterol; 2015 Jul; 15():94. PubMed ID: 26219821
[TBL] [Abstract][Full Text] [Related]
30. Immunocompetent Mouse Models of Multiple Myeloma: Therapeutic Implications.
Du MT; Bergsagel PL; Chesi M
Hematol Oncol Clin North Am; 2024 Apr; 38(2):533-546. PubMed ID: 38233233
[TBL] [Abstract][Full Text] [Related]
31. Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in T(4;14) multiple myeloma.
Xie Z; Gunaratne J; Cheong LL; Liu SC; Koh TL; Huang G; Blackstock WP; Chng WJ
Oncotarget; 2013 Jul; 4(7):1008-18. PubMed ID: 23900284
[TBL] [Abstract][Full Text] [Related]
32. Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myeloma.
Rasmussen T; Haaber J; Dahl IM; Knudsen LM; Kerndrup GB; Lodahl M; Johnsen HE; Kuehl M
Haematologica; 2010 Oct; 95(10):1730-7. PubMed ID: 20511669
[TBL] [Abstract][Full Text] [Related]
33. Many multiple myelomas: making more of the molecular mayhem.
Chesi M; Bergsagel PL
Hematology Am Soc Hematol Educ Program; 2011; 2011():344-53. PubMed ID: 22160056
[TBL] [Abstract][Full Text] [Related]
34. Advances in biology of multiple myeloma: clinical applications.
Hideshima T; Bergsagel PL; Kuehl WM; Anderson KC
Blood; 2004 Aug; 104(3):607-18. PubMed ID: 15090448
[TBL] [Abstract][Full Text] [Related]
35. A novel transgenic mouse model of the human multiple myeloma chromosomal translocation t(14;16)(q32;q23).
Morito N; Yoh K; Maeda A; Nakano T; Fujita A; Kusakabe M; Hamada M; Kudo T; Yamagata K; Takahashi S
Cancer Res; 2011 Jan; 71(2):339-48. PubMed ID: 21224354
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients.
Keats JJ; Maxwell CA; Taylor BJ; Hendzel MJ; Chesi M; Bergsagel PL; Larratt LM; Mant MJ; Reiman T; Belch AR; Pilarski LM
Blood; 2005 May; 105(10):4060-9. PubMed ID: 15677557
[TBL] [Abstract][Full Text] [Related]
37. [Molecular mechanism of oncogenesis and progression in human myeloma].
Kawano MM; Otsuyama K
Nihon Rinsho; 2007 Dec; 65(12):2187-93. PubMed ID: 18069259
[TBL] [Abstract][Full Text] [Related]
38. Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14).
Guglielmelli T; Giugliano E; Cappia S; Papotti M; Saglio G
Cancer Genet Cytogenet; 2007 Feb; 173(1):51-6. PubMed ID: 17284370
[TBL] [Abstract][Full Text] [Related]
39. Impact of Genes Highly Correlated with MMSET Myeloma on the Survival of Non-MMSET Myeloma Patients.
Wu SP; Pfeiffer RM; Ahn IE; Mailankody S; Sonneveld P; van Duin M; Munshi NC; Walker BA; Morgan G; Landgren O
Clin Cancer Res; 2016 Aug; 22(16):4039-44. PubMed ID: 26847058
[TBL] [Abstract][Full Text] [Related]
40. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
